Cargando…
Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. The standard curative treatment is surgical resection, but the treatment of locally advanced and metastatic disease apart from radiotherapy is currently based on cemiplimab. Cemiplimab has demonstrated eff...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600858/ https://www.ncbi.nlm.nih.gov/pubmed/36290893 http://dx.doi.org/10.3390/curroncol29100616 |
_version_ | 1784816933448712192 |
---|---|
author | Pabianek, Marta Lesiak, Aleksandra Nejc, Dariusz Kuncman, Łukasz Narbutt, Joanna Skibińska, Małgorzata Ciążyńska, Magdalena |
author_facet | Pabianek, Marta Lesiak, Aleksandra Nejc, Dariusz Kuncman, Łukasz Narbutt, Joanna Skibińska, Małgorzata Ciążyńska, Magdalena |
author_sort | Pabianek, Marta |
collection | PubMed |
description | Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. The standard curative treatment is surgical resection, but the treatment of locally advanced and metastatic disease apart from radiotherapy is currently based on cemiplimab. Cemiplimab has demonstrated efficacy in the treatment of advanced and metastatic cSCC in clinical trials, although real-world data are still limited. We present four cases of cSCC, which showed a tremendous response to cemiplimab—one patient achieved complete response and three of them achieved partial response. Immunotherapy with cemiplimab, a recently approved PD1 inhibitor, is an important addition to the cutaneous oncology therapeutic options that may be considered in patients with advanced disease not amenable to surgery or radiotherapy. In all four cases, the patients postponed visits to the doctor because of the fear of SARS-CoV-2 infection or for administrative and organizational reasons declared difficult access to doctors caused by the pandemic. |
format | Online Article Text |
id | pubmed-9600858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96008582022-10-27 Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic Pabianek, Marta Lesiak, Aleksandra Nejc, Dariusz Kuncman, Łukasz Narbutt, Joanna Skibińska, Małgorzata Ciążyńska, Magdalena Curr Oncol Case Report Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. The standard curative treatment is surgical resection, but the treatment of locally advanced and metastatic disease apart from radiotherapy is currently based on cemiplimab. Cemiplimab has demonstrated efficacy in the treatment of advanced and metastatic cSCC in clinical trials, although real-world data are still limited. We present four cases of cSCC, which showed a tremendous response to cemiplimab—one patient achieved complete response and three of them achieved partial response. Immunotherapy with cemiplimab, a recently approved PD1 inhibitor, is an important addition to the cutaneous oncology therapeutic options that may be considered in patients with advanced disease not amenable to surgery or radiotherapy. In all four cases, the patients postponed visits to the doctor because of the fear of SARS-CoV-2 infection or for administrative and organizational reasons declared difficult access to doctors caused by the pandemic. MDPI 2022-10-16 /pmc/articles/PMC9600858/ /pubmed/36290893 http://dx.doi.org/10.3390/curroncol29100616 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Pabianek, Marta Lesiak, Aleksandra Nejc, Dariusz Kuncman, Łukasz Narbutt, Joanna Skibińska, Małgorzata Ciążyńska, Magdalena Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic |
title | Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic |
title_full | Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic |
title_fullStr | Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic |
title_full_unstemmed | Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic |
title_short | Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic |
title_sort | promising immune treatment of advanced cutaneous squamous cell carcinoma with cemiplimab—real-world experience in the global sars-cov-2 pandemic |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600858/ https://www.ncbi.nlm.nih.gov/pubmed/36290893 http://dx.doi.org/10.3390/curroncol29100616 |
work_keys_str_mv | AT pabianekmarta promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic AT lesiakaleksandra promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic AT nejcdariusz promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic AT kuncmanłukasz promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic AT narbuttjoanna promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic AT skibinskamałgorzata promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic AT ciazynskamagdalena promisingimmunetreatmentofadvancedcutaneoussquamouscellcarcinomawithcemiplimabrealworldexperienceintheglobalsarscov2pandemic |